Thera-SAbDab

BELIMUMAB

>   Structural Summary
TherapeuticBelimumab
TargetTNFSF13B/CD257/BAFF
Heavy ChainQVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS
Light ChainSSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL
100% seqID Fv Structure5y9j [Fvs: HL], 5y9k [Fvs: HL], 6fxn [Fvs: DE, FG, HI, MN, OP, QR]
99% seqID Fv StructureNone
95-98% seqID Fv Structure6erx [Fvs: DE, FG, HI, MN, OP, QR]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Belimumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 96.97%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
belimumab Q V Q L Q Q S G A E V K K P G S S V R V S C K A S G G T F N N N A I N W V R Q A P G Q G L E W M G G I I P M F G T A K Y S Q N F Q G R V A I T A D E S T G T A S M E L S S L R S E D T A V Y Y C A R S R D L L L F P H H A L S P W G R G T M V T V S S
6erx Q V Q L Q Q S G A E V K K P G S S V R V S C K A S G G T F N N N A I N W V R Q A P G Q G L E W M G G I I P M F G T A K Y S Q N F Q G R V A I T A D E S T S T A S M E L S S L R S E D T A V Y Y C A R S R D L L L F P H Y G M D V W G R G T M V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
belimumab S S E L T Q D P A V S V A L G Q T V R V T C Q G D S L R S Y Y A S W Y Q Q K P G Q A P V L V I Y G K N N R P S G I P D R F S G S S S G N T A S L T I T G A Q A E D E A D Y Y C S S R D S S G N H W V F G G G T E L T V L
6erx S S E L T Q D P A V S V A L G Q T V R V T C Q G D S L R S Y Y A S W Y Q Q K P G Q A P V L V I Y G K N N R P S G I P D R F S G S S S G N T A S L T I T G A Q A E D E A D Y Y C N S R D S S G N H W V F G G G T E L T V L
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '24)Approved
Estimated Status (Aug '24)Active
Recorded Developmental TechnologyCAT Phage Display
INN Year Proposed2003
INN Year Recommended2004
Companies InvolvedAssistance Publique Hopitaux de Paris, Cancer Trials Australia, GlaxoSmithKline, Hospital for Special Surgery, Human Genome Sciences, North Shore-Long Island Jewish Health System, University of Alabama at Birmingham, University of Pennsylvania, University of Wisconsin-Madison, Washington University School of Medicine, Cambridge Antibody Technology
Conditions ApprovedSystemic lupus erythematosus, Lupus nephritis
Conditions ActiveAnti-neutrophil cytoplasmic antibody-associated vasculitis, Myositis, Emphysema, Membranous glomerulonephritis, Myasthenia gravis, Renal transplant rejection, Systemic scleroderma, Graft-versus-host disease
Conditions DiscontinuedWaldenstrom's macroglobulinaemia, Rheumatoid arthritis, Sjogren's syndrome
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy